SuperworthMaravai Lifesciences price to free cash flow MRVI
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 37.2×
- May 2024
- 5-year median
- 9.4×
- 5-year range
- 5.8× to 37.2×
- Peer median
- 8.1×
Maravai Lifesciences' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in May 2024, at 37.2×.
On the days it had one over the last 5 years, its median was 9.4×, from 5.8× in Oct 2023 to 37.2× in May 2024.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2024 | 37.2× | 8.1× | 37.2× |
| 2023 | 10.1× | 5.8× | 10.2× |
| 2022 | 7.6× | 7.1× | 29.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Maravai Lifesciences' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| MRVIMaravai Lifesciences | n/m |
| HRMYHarmony Biosciences | n/m |
| ANIPANI Pharmaceuticals | 9.6× |
| PBHPrestige Consumer Healthcare | 9.6× |
| PAHCPhibro Animal Health | 160× |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 8.1× |
| NRIXNurix Therapeutics | 7.5× |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 7.0× |
| OGNOrganon | 6.4× |
| Peer median | 8.1× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Maravai Lifesciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.